GlassScriptPhysician profile
David B Renner
NPI 1588671077
$4,509.01
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,577 · 2022: $1,914 · 2024: $18.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,302.82 | 2021-2022 | |
| Csl Behring | $592.30 | 2021-2022 | |
| Glaxosmithkline, LLC. | $495.42 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.58 | 2021-2022 | |
| Genzyme Corporation | $296.49 | 2021-2022 | |
| Amgen INC. | $244.73 | 2021-2022 | |
| Pharming Healthcare, INC. | $227.24 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $220.91 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $152.36 | 2021-2022 | |
| Grifols USA, LLC | $149.69 | 2021-2022 | |
| Optinose US, INC. | $113.84 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $110.75 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $83.36 | 2021-2022 | |
| Genentech USA, INC. | $65.52 | 2021-2022 | |
| Kaleo, INC. | $48.22 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $32.60 | 2021-2022 | |
| Incyte Corporation | $22.15 | 2022 | |
| Globus Medical, INC. | $18.75 | 2024 | Precice Intramedullary Limb Lengthening System |
| Merck Sharp & Dohme LLC | $15.63 | 2021 | |
| Leo Pharma INC. | $14.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Renner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.